Cait Lamberton of the Wharton School weighed in on how the FDA’s recommendation to pause distribution of Johnson & Johnson’s COVID-19 vaccine will affect the company’s reputation. “I don’t think this is going to be a huge dagger in J&J’s heart,” she said. “They’ve seen this stuff before. They’ve had plenty of product crises.”

April 13, 2021 ・ From The Wall Street Journal